Preferred Label : Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen;
NCIt synonyms : Bortezomib/Daratumumab/Dexamethasone/Lenalidomide; Daratumumab-RVD; RVD Regimen Plus Daratumumab; Darzalex-RVD; D-RVD Regimen; Bortezomib-Lenalidomide-Dexamethasone Plus Daratumumab; Bortezomib/Lenalidomide/Dexamethasone Plus Daratumumab; Bortezomib/Lenalidomide/Dexamethasone Plus Daratumumab Regimen; Bortezomib-Daratumumab-Dexamethasone-Lenalidomide; Velcade/Revlimid/Dexamethasone-Darzalex; Bortezomib-Daratumumab-Dexamethasone-Lenalidomide Regimen; RVD Plus Darzalex; Dara-RVd;
NCIt definition : A regimen consisting of bortezomib, daratumumab, dexamethasone and lenalidomide that
can be used for the treatment of plasma cell (multiple) myeloma.;
NCI Metathesaurus CUI : CL1664476;
Codes from synonyms : 6472;
Origin ID : C181580;
UMLS CUI : C5557164;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3610014/fr/darzalex-daratumumab-myelome-multiple
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
Bortezomib/Daratumumab/Dexamethasone/Lenalidomide Regimen
Bortezomib
dexamethasone
Lenalidomide
antineoplastic agents
daratumumab
hematopoietic stem cell transplantation
transplantation, autologous
evaluation of the transparency committee
multiple myeloma
daratumumab
---
